



Boule Diagnostics – Information on the decided division of shares (stock split 4:1)

In accordance with the decision made on the Annual General Meeting (“AGM”) of Boule Diagnostics AB (“Boule”) on May 14, 2018, a division of Boule’s shares will be implemented, whereby each existing share will be divided into four shares (so called stock split 4:1). The division will not affect Boule’s share capital but will change the share’s quotient value from SEK 1 per share to SEK 0,25 per share.

The Board has, through the decision of the AGM, been authorized to determine the record date of the split. The record date of the split has been decided to occur on June 4, 2018.

Time table for the division of shares

Thursday, May 31, 2018:	Final day for trading before the division of shares
Friday, June 1, 2018:	First day for trading after the division of shares
Monday, June 4, 2018:	Record date, Euroclear Sweden AB

Shareholders need not take any action due to the division of the company’s shares. After the division of shares, Boule’s total number of shares will increase from 4,854,138 shares to 19,416,552 shares.

As of Friday, June 1, 2018, Boules shares will be traded with the new ISIN code: SE0011231158.

For further information, please contact:

Peter Ehrenheim, Chairman of the Board Boule Diagnostics AB, phone 0706-67 57 11
Fredrik Dalborg, CEO and Group President Boule Diagnostics AB, phone 070-558 51 05

About Boule Diagnostics AB (publ)

Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA and Mexico. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com